IONIQ Sciences Finalist in National ‘Buzz of BIO’ Awards
March 1, 2021
Utah’s own IONIQ Sciences was named a finalist for the prestigious ‘Buzz of BIO 2021’ award in the ‘Diagnostic and Beyond’ category. Although IONIQ did not win the category, being among the top finalists is a signiicant distinction. Placement was determined by companies receiving the most votes.
“We’re on a mission to modernize cancer detection with Electrical Impedance Analytics and our patented algorithm,” said Jared Bauer, CEO of IONIQ Sciences. “External recognition, like the Buzz of BIO and the FDA Breakthrough Device designation that we received earlier, means people, healthcare systems and organizations and are listening and now even more will hear about us. The recognition is invigorating. Here’s a heartfelt thank you to all of our supporters.”
“We congratulate IONIQ for achieving this well-deserved allocade from the world’s largest biotechnology organization,” said Kelvyn Cullimore, president and CEO of BioUtah.
The annual ‘Buzz of BIO’ contest provides an excellent opportunity for companies looking to make the connections needed to take their product to the next phase. This year, companies were nominated in each of the following three categories:
- Diagnostics and Beyond
- Pipelines of Promise
- Technologies of Tomorrow
Recent News
- Myriad Genetics Highlights New Research Advancements and Oncology Innovations at 2025 ASCO Annual Meeting
- BD to Initiate Real-World Patient Data Registry for the Rotarex™ Atherectomy System in Treatment of Peripheral Artery Disease
- Lessons in Innovation: Clark Turner’s Impact on Medical Imaging
- Merit Medical Acquires Biolife Delaware
- Pathos AI Secures $365 Million in Series D Financing to Advance Oncology Drug Development Through AI
- BD Launches Landmark Cell Analyzer Featuring Breakthrough Spectral and Real-Time Cell Imaging Technologies
